PANCREATIC CANCER (PC) is one of the most lethal malignancies.[1](#jmri27024-bib-0001){ref-type="ref"} For patients with resectable disease, initial surgery combined with adjuvant chemotherapy are the first‐line treatments. However, the prognosis of these patients is still poor and early recurrence (ER) is observed in 35--50% patients within 1 year after surgery.[1](#jmri27024-bib-0001){ref-type="ref"}, [2](#jmri27024-bib-0002){ref-type="ref"}, [3](#jmri27024-bib-0003){ref-type="ref"} Hence, evaluation of ER risk and identifying those patients with increased risk of relapse are necessary and urgent.

Imaging studies provide valuable information to predict ER after surgery in a wide range of malignancies. Conventional criteria, such as the tumor‐node‐metastasis (TNM) staging system, stratify patients using three major parameters on images: primary tumor, regional lymph nodes, and distant metastases.[4](#jmri27024-bib-0004){ref-type="ref"} Although these imaging criteria are fundamental to establish a prognostic risk evaluation, their application is limited. Moreover, there was a significant difference in survival among patients in identical stages.[4](#jmri27024-bib-0004){ref-type="ref"}, [5](#jmri27024-bib-0005){ref-type="ref"} One explanation is that conventional criteria mainly focus on the anatomical radiological features. This might oversimplify the complexity of a tumor\'s biological behavior, which is highly correlated with ER in patients. Therefore, the current stratification system needs to be improved and the identification of patients with increased risk of recurrence remains challenging for surgeons and oncologists.

In 2012, Lambin et al first presented the concept of "Radiomics."[6](#jmri27024-bib-0006){ref-type="ref"} The conventional criteria mainly focus on the anatomical radiological features. This might oversimplify the complexity of tumor improvement and behavior. Radiomics focuses on improvements of image analysis, using an automated high‐throughput extraction of large amounts of quantitative features of medical images. It provides more and better information than that of a conventional approach.[6](#jmri27024-bib-0006){ref-type="ref"} Hundreds of quantitative features could be extracted from original imaging using a high‐throughput approach and could be further analyzed. Recently, research has revealed the links between radiomics and underlying tumor biology in a wide range of malignant diseases, which are strongly correlated with tumor phenotype, aggressiveness, response to treatment, and prognosis.[7](#jmri27024-bib-0007){ref-type="ref"}, [8](#jmri27024-bib-0008){ref-type="ref"}, [9](#jmri27024-bib-0009){ref-type="ref"}, [10](#jmri27024-bib-0010){ref-type="ref"} Previous studies have shown that radiomics has the potential to predict ER in such malignancies as chondrosarcoma, hepatocellular carcinoma, and cholangiocarcinoma, which indicated that radiomics might provide surgeons with useful information in the anticipated era of precision medicine.[11](#jmri27024-bib-0011){ref-type="ref"}, [12](#jmri27024-bib-0012){ref-type="ref"}, [13](#jmri27024-bib-0013){ref-type="ref"} Kaissis et al recently developed several machine‐learning models for the prediction of survival in PC based on radiomics features. The results showed that radiomics features were significantly associated with molecular subtypes of PC.[14](#jmri27024-bib-0014){ref-type="ref"}, [15](#jmri27024-bib-0015){ref-type="ref"} While these results are promising and encouraging, radiomic research in recurrence risk of PC is limited, which may due to limited data in current studies.

In this study we aimed to develop a radiomic feature‐based nomogram to stratify resectable PC patients with high ER risks preoperatively. This model could provide surgeons with valuable information and potentially serve as reliable reference for clinical practice.

Materials and Methods {#jmri27024-sec-0011}
=====================

*Patients* {#jmri27024-sec-0012}
----------

Data were obtained from medical centers A and B. This study was approved by Institutional Review Board of two centers. Between April 2012 to July 2018, patients who were diagnosed with PC and further underwent upfront surgery in the two institutions were included in this study. The exclusion criteria were: 1) Patients who did not receive a magnetic resonance imaging (MRI) scan within two weeks before surgery. 2) Patients lacking complete clinical data. 3) Patients lacking complete follow‐up data. 4) Patients who were restaged as borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) postoperatively. 5) Patients who died from surgical complications within 30 days after surgery. The inclusion criteria were met by 303 patients who were then enrolled in this study. A flowchart of this study is shown in Fig. [1](#jmri27024-fig-0001){ref-type="fig"}. Patients were then divided into an ER group (disease‐free survival ≤12 months) and a nonearly recurrence (NER) group (disease‐free survival \>12 months) according to previous studies, which indicated an optimal cutoff of 12 months for identifying the ER group and late recurrence group based on overall survival and survival after recurrence.[1](#jmri27024-bib-0001){ref-type="ref"}, [2](#jmri27024-bib-0002){ref-type="ref"} The preoperation MRI scans of the included patients were used to extract the radiomic features. The training cohort and internal validation cohort comprised patients from medical center A treated between April 2012 to July 2018. Patients from medical center B treated between April 2012 to July 2018 were included as the external validation cohort.

![Flowchart showing the patient inclusion criteria and the study design.](JMRI-52-231-g001){#jmri27024-fig-0001}

*Clinical Data and Follow‐up* {#jmri27024-sec-0013}
-----------------------------

The included patients were evaluated by a multidisciplinary team that comprised oncologists, radiologists, and surgeons. The clinical parameters including gender, age, symptoms, clinical stage, location of the tumor, laboratory examination results, surgical margin, and tumor differentiation were extracted from the electronic medical records system. The tumors\' clinical stage was assessed using the AJCC guidelines (8^th^ ed.).[4](#jmri27024-bib-0004){ref-type="ref"} Chest high‐resolution computed tomography (HRCT), contrast‐enhanced MRI, and abdominal contrast‐enhanced computed tomography (CE‐CT) were performed every 2 months during the first year after surgery. Serum tumor biomarkers were tested every month after surgery. Once CT or MRI showed a sign of new local or distant lesion, the recurrence was confirmed. The status and the time was recorded as the date of first CT or MRI that showed disease progression.

*MR Image Acquisition* {#jmri27024-sec-0014}
----------------------

All imaging data include four sets of images from three different scans: Preoperative T~1~‐w, T~2~‐w, CET~1~‐w arterial phase, and CET~1~‐w portal venous phase MR images. The T~1~‐w and CET~1~‐w images were acquired under breath‐hold and T~2~ image were acquired with a respiratory trigger.

In center A, preoperative MRI was performed with a 3.0T MR scanner (Discovery MR 750; GE Healthcare, Waukesha, WI). The parameters were as follows: T~1~‐w: repetition time (TR) = 4.1 msec, echo time (TE) = 2.4 msec, slice thickness = 3 mm, matrix = 260 × 224, and field of view (FOV) = 36\*36 cm; T~2~‐w: TR = 12,000 msec, TE = 72 msec, slice thickness = 3 mm, matrix = 320\*320, and FOV = 36\*36 cm; Contrast‐enhanced imaging was performed following the intravenous injection of 0.1 mmol/kg contrast medium (Gadodiamide, GE Healthcare), rate = 2 mL/s. The arterial phase and portal venous phase (20 and 60 sec postinjection, respectively) were collected. TR = 3.9 msec, TE = 2.2 msec, slice thickness =3 mm, matrix = 260\*224, and FOV = 36 × 36 cm.

In center B, preoperative MRI was performed with a 3.0T system (Discovery MR750; GE Healthcare). The parameters were as follows: T~1~‐w: TR = 3.9 msec, TE = 1.2 msec, the slice thickness = 3 mm; matrix = 256 × 256, and FOV = 38\*38 cm. T~2~‐w: TR = 6000--8000 msec, TE = 91 msec, slice thickness = 4 mm; matrix = 256 × 256, and FOV = 38\*38 cm. Contrast‐enhanced imaging was performed following the intravenous injection of 0.1 mmol/kg contrast medium (Gadodiamide, GE Healthcare), rate = 2 mL/s. The imaging delay time for arterial phase and portal venous phase was 20 sec and 50 sec, respectively. TR = 3.8 msec, TE = 1.7 msec, FOV = 380 × 300 mm, matrix = 320\*224, slice thickness = 3.2 mm.

*Region of Interest and Segmentation and Extraction of Radiomic Features* {#jmri27024-sec-0015}
-------------------------------------------------------------------------

Preoperative T~1~‐w, T~2~‐w, arterial phase imaging, and portal venous phase imaging were used to extract the features (Supplemental Fig. [5](#jmri27024-supitem-0001){ref-type="supplementary-material"}). The AK software (Artificial Intelligence Kit v. 3.1.0.A, GE Healthcare) was used to process the images before extracting the features. The Supplemental Material shows the details of imaging preprocessing. The regions of interest (ROIs) were manually contoured on MR by the radiologists. Contrast‐enhanced CT was used as the reference. The two radiologists (X.W.B. and Y.S.H.), who both had more than 10 years experience of interpreting abdominal images, were blinded to the clinical outcome before ROI segmentation. All ROIs were segmented using ITK‐SNAP v. 3.6.0 from UPenn ([www.itksnap.org](http://www.itksnap.org)).[16](#jmri27024-bib-0016){ref-type="ref"} In total, 328 radiomic features were extracted from each MRI sequence using the AK software. The radiomic features extracted included: histograms, form factor parameters, GLCM (gray level co‐occurrence matrix), and RLM (run length matrix). All extracted radiomic features were individually subtracted by the mean value of each feature and divided by the respective standard deviation values (Z‐score normalization), thus removing the limitations imposed by the units of each feature. In the primary cohort, patients were randomly divided into two groups comprising the training set (*n* = 123) and the internal validation set (*n* = 54), with a proportion of 7:3. From the training set, the most useful predictive radiomic features were selected using LASSO (least absolute shrinkage and selection operator) regression, which is suitable for the regression of high‐dimension data. The details of the features selection are shown in the Supplemental Material. After the optimal radiomic features were selected from the training set, a linear combination of selected features weighted by their respective coefficients were used to calculate a radiomic signature to predict ER after surgery for each patient. The area under the receiver‐operator characteristic (ROC) curve (AUC) was used to evaluate the predictive accuracy of the radiomic signature in both the training and testing groups.

*Intraobserver and Interobserver Agreement* {#jmri27024-sec-0016}
-------------------------------------------

To determine the intra‐ and interobserver reproducibility of radiomic features extraction, the intra‐ and interclass correlation coefficients (ICC) were calculated. Thirty images were chosen randomly for ROI segmentation by two radiologists who both had more than 10 years experience of interpreting abdominal images. The performances of two radiologists (A and B) were used to assess the interobserver ICC. The performance of one radiologist (A), who repeated the segmentation of the tumors, was used to assess the intraobserver ICC. An ICC greater than 0·8 was considered to represent good agreement of the feature extraction.

*Radiomic Nomogram Development* {#jmri27024-sec-0017}
-------------------------------

Univariate logistic regression was first used to identify potential predictors. Then multivariate logistic regression was used to select the independent predictors of ER, which were subsequently used to develop a novel radiomic nomogram. The training and validation cohorts were used to test the calibration and discrimination performances of the radiomic nomogram. A calibration curve displayed the agreement between the predicted and observed risks of ER and was used to assess the calibration performance. The AUC was used to measure the discrimination performance. The radiomic nomogram was validated using the independent validation cohort of 126 patients from the second hospital.

Decision curve analysis (DCA) was used to assess the clinical utility of the radiomic nomogram model in the three cohorts (training, internal, and independent validation). The \"true\" positive and weighted false‐positive rates were calculated across different threshold probabilities in the validation set to determine the net benefit. Specifically, the weighting factor was defined as the specific value of the threshold probability divided by 1 minus the threshold probability. A higher true‐positive rate and a relatively low false‐positive rate were suggested by a high net benefit. Plotting the net benefit against the threshold probability across the range of 0 to 0·8 generated the decision curve. We also plotted the DCA for the radiomic signature.

*Statistical Analysis* {#jmri27024-sec-0018}
----------------------

Continuous variables are expressed as mean and standard deviation (SD), whereas categorical variables are expressed as the frequency and proportion. The chi‐squared test or Fisher\'s exact test were used to analyze the categorical variables, when appropriate. The Mann--Whitney *U*‐test, or independent‐sample *t*‐test were used to assess the continuous variables, when appropriate. Penalty parameter tuning combined with the LASSO logistic regression model were performed using 10‐fold cross‐validation based on the minimum criteria. The likelihood ratio test was used for backward stepwise selection, which used Akaike\'s information criterion (AIC) as the stopping rule. Certain statistical analyses were conducted using R software (v. 3.5.1, Vienna, Austria). The \"glmnet\" package in R was used to perform LASSO logistic regression. The \"rms\" package was used for nomogram construction and calibration plotting. ROC plots were constructed using the \"pROC\" package. The \"rmda\" package was used to construct the DCA curve plots. The \"rms\" package in R was used to calibrate the radiomic signature using the calibration curve. SPSS 18.0 (IBM, Armonk, NY) and MedCalc software v. 15.2.2 (<https://www.medcalc.org/>) were used to perform the statistical analysis. Statistical significance was accepted at *P* \< 0.05.

Results {#jmri27024-sec-0019}
=======

*Characteristics of the Patients* {#jmri27024-sec-0020}
---------------------------------

This study included 303 patients and flowcharts of the study are shown in Figs. [1](#jmri27024-fig-0001){ref-type="fig"} and [2](#jmri27024-fig-0002){ref-type="fig"}. A total of 177 patients from the first medical center were divided into a training cohort (*n* = 123) and an internal validation cohort (*n* = 54). Patients from the second medical center were used as the external independent validation cohort (*n* = 126). Tables [1](#jmri27024-tbl-0001){ref-type="table"} and [2](#jmri27024-tbl-0002){ref-type="table"} show the patients\' characteristics. Between the two centers, no difference in the ER rate was observed (74/177, 42.4% vs. 55/126, 43.7%, *P* = 0.749) nor was a difference observed for the other clinical parameters (age, gender, pain, weight loss, tumor markers level, and clinical stage). Early relapse was detected in 130 patients; local recurrence (*n* = 48, 36.9%) and hepatic recurrence (*n* = 51, 39.2%) were the most common type of relapse; other types of relapse were observed in 23.3% patients (*n* = 31, 23.8%). The pathological results showed that a complete R0 resection was achieved in 79% (*n* = 140) and 81% (*n* = 102) of the patients from the two medical centers, respectively. Adjuvant chemotherapy was implemented in 60·4% (*n* = 107) and 65·9% (*n* = 83) of the patients after surgery.

![Workflow of the development of the radiomic signature.](JMRI-52-231-g002){#jmri27024-fig-0002}

###### 

Characteristics of the Study Population

                          Training cohort (*n =* 123)   Internal validation cohort (*n =* 54)   External validation cohort (*n =* 126)                        
  ----------------------- ----------------------------- --------------------------------------- ---------------------------------------- ------- ----- ------ -------
  Age, years                                                                                                                             0.839                
  ≥ 60                    71                            57.7                                    33                                       61.1    71    56.3   
  \< 60                   52                            42.3                                    21                                       38.9    55    43.7   
  Gender                                                                                                                                 0.859                
  Male                    83                            67.5                                    35                                       64.8    81    64.3   
  Female                  40                            32.5                                    19                                       35.2    45    35.7   
  Location                                                                                                                               0.403                
  Proximal                90                            73.2                                    38                                       70.4    93    73.8   
  Distal                  33                            26.8                                    16                                       29.6    33    26.2   
  Pain                                                                                                                                   0.414                
  Yes                     76                            61.8                                    33                                       61.1    68    54.0   
  No                      47                            38.2                                    21                                       38.9    58    46.0   
  Weight loss                                                                                                                            0.847                
  Yes                     61                            49.6                                    29                                       53.7    62    49.2   
  No                      62                            50.4                                    25                                       46.3    64    50.8   
  CA199, kU/L                                                                                                                            0.636                
  Normal                  44                            35.8                                    22                                       40.7    42    33.3   
  Elevated                79                            64.2                                    32                                       59.3    84    66.7   
  CEA, ng/mL                                                                                                                                                  
  Normal                  102                           82.9                                    46                                       85.2    104   82.5   0.906
  Elevated                21                            17.1                                    8                                        14.8    22    17.5   
  TB, μmol/L                                                                                                                                                  
  Normal                  65                            52.8                                    28                                       51.9    76    60.3   0.403
  Elevated                58                            47.2                                    26                                       48.1    50    39.7   
  Albumin, g/L                                                                                                                                                
  Normal                  85                            69.1                                    41                                       75.9    85    67.5   0.520
  Decreased               38                            30.9                                    13                                       24.1    41    32.5   
  Stage                                                                                                                                  0.541                
  I                       49                            39.8                                    21                                       38.9    39    31.0   
  II                      61                            49.6                                    26                                       48.1    67    53.2   
  III                     13                            10.5                                    7                                        12.9    20    15.9   
  IV                      0                             0                                       0                                        0       0     0      
  Adjuvant chemotherapy                                                                                                                  0.459                
  Yes                     72                            58.5                                    35                                       64.8    83    65.9   
  No                      51                            41.5                                    19                                       35.2    43    34.1   

TB: total bilirubin; CEA: carcinoembryonic antigen.

*\*P \<* 0.05.

###### 

Preoperative Clinical Characteristics of Patients With or Without ER

                       Training cohort (*n =* 123)   Internal validation cohort (*n =* 54)   External validation cohort (*n =* 126)                                                                                                                                
  -------------------- ----------------------------- --------------------------------------- ---------------------------------------------------- -------------- ------------- ---------------------------------------------------- -------------- --------------- ----------------------------------------------------
  Age, years                                                                                 0.835                                                                             0.924                                                                               0.808
  ≥ 60                 41                            30                                                                                           18             15                                                                 42             29              
  \< 60                31                            21                                                                                           12             9                                                                  29             26              
  Gender                                                                                     0.580                                                                             0.799                                                                               0.102
  Male                 50                            33                                                                                           19             16                                                                 50             31              
  Female               22                            18                                                                                           11             8                                                                  21             24              
  Pain                                                                                       0.575                                                                             0.454                                                                               0.909
  Yes                  43                            33                                                                                           17             16                                                                 38             30              
  No                   29                            18                                                                                           13             8                                                                  33             25              
  Weight loss                                                                                0.175                                                                             0.246                                                                               0.487
  Yes                  32                            29                                                                                           14             15                                                                 33             29              
  No                   40                            22                                                                                           16             9                                                                  38             26              
  Location                                                                                   0.171                                                                             0.505                                                                               0.289
  Proximal             56                            34                                                                                           20             18                                                                 55             38              
  Distal               16                            17                                                                                           10             6                                                                  16             17              
  CA199, kU/L                                                                                \<0.001[*\**](#jmri27024-note-0006){ref-type="fn"}                                0.035[*\**](#jmri27024-note-0006){ref-type="fn"}                                    0.001[*\**](#jmri27024-note-0006){ref-type="fn"}
  Normal               36                            8                                                                                            16             6                                                                  32             10              
  Elevated             36                            43                                                                                           14             18                                                                 39             45              
  CEA, ng/mL                                                                                 0.731                                                                             0.134                                                                               0.257
  Normal               59                            43                                                                                           28             18                                                                 61             43              
  Elevated             13                            8                                                                                            2              6                                                                  10             12              
  TB, μmol/L                                                                                 0.043[*\**](#jmri27024-note-0006){ref-type="fn"}                                  0.429                                                                               0.503
  Normal               43                            21                                                                                           17             11                                                                 41             35              
  Elevated             29                            30                                                                                           13             13                                                                 30             20              
  Albumin, g/L                                                                               0.374                                                                             0.255                                                                               0.731
  Normal               52                            33                                                                                           21             20                                                                 47             38              
  Decreased            20                            18                                                                                           9              4                                                                  24             17              
  Stage                                                                                      \<0.001[*\**](#jmri27024-note-0006){ref-type="fn"}                                0.104                                                                               0.002[*\**](#jmri27024-note-0006){ref-type="fn"}
  I                    39                            10                                                                                           15             6                                                                  31             8               
  II                   30                            31                                                                                           13             13                                                                 32             35              
  III                  3                             10                                                                                           2              5                                                                  8              12              
  IV                   0                             0                                                                                            0              0                                                                  0              0               
  Radiomic signature   --1.44±0.147                  0.179±0.221                             \<0.001[*\**](#jmri27024-note-0006){ref-type="fn"}   --1.39±0.327   0.743±0.358   \<0.001[*\**](#jmri27024-note-0006){ref-type="fn"}   --1.13±0.155   --0.471±0.243   \<0.001[*\**](#jmri27024-note-0006){ref-type="fn"}

TB: total bilirubin; CEA: carcinoembryonic antigen.

*P \<* 0.05.

*Intra‐ and Interobserver Agreement* {#jmri27024-sec-0021}
------------------------------------

The intraobserver reproducibility showed ICC values of 0·841 to 0·928, and the interobserver ICCs were 0·829 to 0·863. The results showed favorable intra‐ and interobserver reproducibility of the feature extraction.

*Development of the Radiomic Signature* {#jmri27024-sec-0022}
---------------------------------------

A total of 1312 radiomic features were extracted from each patient. Mann--Whitney tests and analysis of variance (ANOVA) tests allowed the selection of 427 features, among which 57 were identified by Spearman correlation analysis. Combined features( T~1~‐w+T~2~‐w+CET~1~‐w) showed higher performance than other individual sequences (Supplemental Fig. [4](#jmri27024-supitem-0001){ref-type="supplementary-material"} and Supplemental Table [2](#jmri27024-supitem-0001){ref-type="supplementary-material"}). Finally, 10 radiomic features (two from T~1~‐w imaging, three from T~2~‐w imaging, one feature from CET~1~‐w arterial phase imaging and four features from CET~1~‐w portal vein phase imaging) were selected after LASSO regression and were used to construct the radiomic signature (Fig. [3](#jmri27024-fig-0003){ref-type="fig"}). The details of the features and the calculation formula for the radiomic signature are shown in Supplemental Table [1](#jmri27024-supitem-0001){ref-type="supplementary-material"} and Supplemental Fig. [1](#jmri27024-supitem-0001){ref-type="supplementary-material"}.

![LASSO logistic regression for texture feature selection. **(a)** In the LASSO model, the penalization parameter λ selection used 10‐fold cross‐validation as the minimum criteria. The log (λ) (x‐axis) was plotted against the partial likelihood deviance (y‐axis). The minimum criteria and the 1‐SE criteria were used to draw the dotted vertical lines at the optimal values **(b)**. For 57 texture features, the LASSO coefficient profiles are shown. Ten‐fold cross‐validation in the log (λ) sequence was used to draw the vertical line at the value selected; also indicate are 10 features with nonzero coefficients.](JMRI-52-231-g003){#jmri27024-fig-0003}

*Evaluation Performance of the Radiomic Signature* {#jmri27024-sec-0023}
--------------------------------------------------

The evaluation performance of the developed radiomic signature was assessed in the three cohorts using ROC curves (Fig. [4](#jmri27024-fig-0004){ref-type="fig"}). In general, the value of the rad‐score was significantly higher in patients who developed ER (Fig. [5](#jmri27024-fig-0005){ref-type="fig"} and Supplemental Fig. [2](#jmri27024-supitem-0001){ref-type="supplementary-material"}). The AUC values were 0.802 (training cohort), 0.807 (internal validation cohort), and 0.781 (external validation cohort). The boxplots of the radiomic signature distribution are shown in Supplemental Fig. [2](#jmri27024-supitem-0001){ref-type="supplementary-material"}. The details of the evaluation performance of the radiomic signature are shown in Table [3](#jmri27024-tbl-0003){ref-type="table"}.

![ROC curve of the ER risk evaluation performance of the radiomic signature in the training cohort **(a)** (AUC = 0.802) the internal validation cohort **(b)** (AUC = 0.807), and the external validation cohort **(c)** (AUC = 0·781).](JMRI-52-231-g004){#jmri27024-fig-0004}

![Dot diagram showing that the value of the rad‐score was significantly higher in patients who developed ER in in the training cohort **(a)**, the internal validation cohort **(b)**, and the external validation cohort **(c)**.](JMRI-52-231-g005){#jmri27024-fig-0005}

###### 

Univariate and Multivariate Logistic Regression Analysis of the Radiomic Signature and Preoperative Clinical Parameters

                        Univariate analysis                   Multivariate analysis                           
  --------------------- --------------------- --------------- ----------------------- ------- --------------- ------------
  Radiomics signature   2.840                 1.796--4.489    \< 0.001\*              2.535   1.576--4.079    \< 0.001\*
  Age ≥ 60 years        0.926                 0.447--1.915    0.835                                           
  Pain                  1.141                 0.716--1.819    0.575                                           
  Weight loss           1.288                 0.884--1.877    0.175                                           
  Gender                1.073                 0.832--1.384    0.580                                           
  Location              1.750                 0.783‐3.913     0.171                                           
  CA19‐9 \> 37kU/L      5.375                 2.219--13.021   \< 0.001\*              3.772   1.224--11.623   0.021\*
  CEA \> 3.4ng/mL       1.151                 0.515--2.573    0.731                                           
  TB \> 17.1 μmol/L     2.118                 1.021--4.395    0.043\*                 1.867   0.688--5.065    0.220
  Albumin \< 35 g/L     1.418                 0.655--3.069    0.374                                           
  TNM stage             3.764                 1.950--7.266    \< 0.001\*              3.748   1.609--8.728    0.002\*

CEA, carcinoembryonic antigen; TB, total bilirubin; CI, confidence internal.

Significant parameters with *P \<* 0.05 in the univariate analysis were included in the multivariate logistic regression analysis.

###### 

Predictive Performance of the Radiomic Signature and Radiomic Nomogram

                               Radiomic signature           Clinical characteristics           Radiomic nomogram                                         
  ---------------------------- -------------------- ------- -------------------------- ------- ------------------- --------------------- ------- ------- ----------------------
  Training cohort              0.681                0.824   0.802 (0.721--0.868)       73.61   70.59               0.757(0.672--0.830)   0.611   0.961   0.871 (0.799--0.925)
  Internal validation cohort   0.867                0.625   0.807 (0.677--0.902)       76.67   62.50               0.739(0.601--0.849)   0.933   0.667   0.876 (0.758--0.950)
  Independent validation       0.727                0.732   0.781 (0.699--0.850)       70.91   66.20               0.718(0.631--0.795)   0.803   0.746   0.846 (0.771--0.904)

AUC, area under the receiver operating characteristic (ROC) curve; CI, confidence interval.

*Development of the Radiomic Nomogram* {#jmri27024-sec-0024}
--------------------------------------

In the univariate analysis, the carbohydrate antigen (CA)19‐9 level, clinical stage, the radiomic signature, and the total bilirubin (TB) level showed significant differences between the ER and non‐ER groups in the training cohort. In multivariate logistic analysis, the radiomic signature (odds ratio \[OR\]: 2.535, 95% confidence interval \[CI\]: 1.576--4.079, *P* \< 0.001), CA19‐9 level (OR: 3.772, 95% CI: 1.224--11.623, *P* = 0.021), and clinical stage (OR: 3.748, 95% CI: 1.609--8.728, *P* = 0.002) were identified as independent parameters of ER. A radiomic nomogram was then developed incorporating the CA19‐9 level and clinical stage. Each factor was assigned a weighted number of points. The total number of points for each patient was calculated using the nomogram, and was associated with an estimated probability of ER (Fig. [6](#jmri27024-fig-0006){ref-type="fig"}).

![The radiomic nomogram incorporating the radiomic signature, the CA19‐9 level, and the clinical stage.](JMRI-52-231-g006){#jmri27024-fig-0006}

*Evaluation Performance of the Radiomic Nomogram* {#jmri27024-sec-0025}
-------------------------------------------------

An ROC curve was used to assess the discriminative ability of the developed nomogram. The AUC values were 0.871 (training cohort), 0.876 (internal validation cohort), and 0.846 (external validation cohort) (Fig. [8](#jmri27024-fig-0008){ref-type="fig"} and Supplemental Fig. [3](#jmri27024-supitem-0001){ref-type="supplementary-material"}).

The radiomic nomogram showed promising evaluation performance in the three cohorts. The calibration curve indicated adequate consistency between estimated risks using the nomogram and the actual observed outcome in the three cohorts (Fig. [7](#jmri27024-fig-0007){ref-type="fig"}). Details of the performance of radiomics nomogram are shown in Table [4](#jmri27024-tbl-0004){ref-type="table"}.

![Calibration curves for the nomogram in the training cohort **(a)**, the internal validation cohort **(b)**, and the external validation cohort **(c)**. The 45° black line represents the reference line showing the \"ideal\" prediction. The dotted line indicates the performance of the radiomic nomogram in ER prediction, and the solid line indicates the correction of bias in the radiomic nomogram.](JMRI-52-231-g007){#jmri27024-fig-0007}

![ROC curve of the ER risk evaluation performance of the radiomic nomogram in the training cohort **(a)** (AUC = 0·871) the internal validation cohort **(b)** (AUC = 0·876), and the external validation cohort **(c)** (AUC = 0·846).](JMRI-52-231-g008){#jmri27024-fig-0008}

![DCA curve of clinical use assessment of the radiomic signature and the radiomic nomogram in the training cohort **(a)**, internal validation cohort **(b)**, and external validation cohort **(c)**. The net benefit is shown on the y‐axis and the threshold probability is shown on the x‐axis. Use of the radiomic nomogram (red line) achieves the highest net benefit compared with the radiomic signature (blue line), clinical characteristics (yellow line), treat‐all strategy (gray line), and the treat‐none strategy (horizontal black line).](JMRI-52-231-g009){#jmri27024-fig-0009}

Finally, we used a DCA curve to assess whether this nomogram would help with clinical treatment strategies (Fig. [9](#jmri27024-fig-0009){ref-type="fig"}). In three cohorts, when the threshold probability varied from 0 to 1, according to the DCA, the radiomic nomogram achieved the most net benefit compared with a \"treat all\" strategy, a \"treat none\" strategy, and the radiomic signature.

Discussion {#jmri27024-sec-0026}
==========

Pancreatic cancer has a poor prognosis, even after surgery. The recurrence rate and survival for patients in identical stages vary greatly.[17](#jmri27024-bib-0017){ref-type="ref"}, [18](#jmri27024-bib-0018){ref-type="ref"} This evidence indicates that PC is a heterogeneous disease and upfront surgery is not suitable for the subgroup of patients with increased risk of ER, even in the early stage.[19](#jmri27024-bib-0019){ref-type="ref"}, [20](#jmri27024-bib-0020){ref-type="ref"} Neoadjuvant chemotherapy (NAC) might be an optimal choice for these patients and could help to eliminate the circulating tumor cells and distant micrometastatic lesions, leading to a reduced ER rate after surgery.[21](#jmri27024-bib-0021){ref-type="ref"} Accumulating evidence demonstrates that patients with BRPC and LAPC could obtain remarkable survival benefit from NAC.[22](#jmri27024-bib-0022){ref-type="ref"}, [23](#jmri27024-bib-0023){ref-type="ref"} Thus, some physicians have started to use NAC in resectable cases.[24](#jmri27024-bib-0024){ref-type="ref"} In guidelines proposed by the National Comprehensive Cancer Network (NCCN), NAC is recommended for high‐risk resectable PC.[25](#jmri27024-bib-0025){ref-type="ref"} However, whether patients with resectable pancreatic cancer (RPC) should receive NAC remains controversial. One of the main challenges is that we lack methods to identify patients who could benefit from upfront surgery. Except for CA19‐9, a severely limited biomarker, no viable prognostic or predictive biomarkers for PC are currently available.[26](#jmri27024-bib-0026){ref-type="ref"}

In the present study we sought to develop a preoperative radiomic nomogram to help identify patients with increased risk of ER. The texture features in our radiomic signature included both high‐ and low‐order radiomic features, which were consistent with previous studies. Histogram parameters (a low‐order radiomic feature), which are related to the properties of individual pixels, describe the distribution of voxel intensities within an image via commonly used and basic metrics.[27](#jmri27024-bib-0027){ref-type="ref"} Histogram feature such as intensity, kurtosis, and skewness, based on enhanced MRI images, reflect the enhancement ratio of a tumor. Previous studies demonstrated that the hypoattenuation value parameter is likely to reflect the degree of tumor necrosis within the tumor tissue and an isoattenuating enhancement pattern might represent a relatively well‐differentiated and less aggressive tumor.[28](#jmri27024-bib-0028){ref-type="ref"}, [29](#jmri27024-bib-0029){ref-type="ref"} High‐order radiomic features, such as GLCM features, measure the spatial relationship between local nearby pixels.[30](#jmri27024-bib-0030){ref-type="ref"} We assumed that high‐order features better reflect the tumor biology and heterogeneity. The prognostic value of the high‐order radiomic texture of MRI has also been proven in various malignancies, including breast cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma.[31](#jmri27024-bib-0031){ref-type="ref"}, [32](#jmri27024-bib-0032){ref-type="ref"}, [33](#jmri27024-bib-0033){ref-type="ref"} A study of preoperative MRI texture analysis conducted by Choi et al showed that tumor size and entropy with medium texture were significantly associated with overall survival in patients with pancreatic ductal adenocarcinoma (PDAC).[34](#jmri27024-bib-0034){ref-type="ref"} However, it remains a challenge to associate a single radiomic feature with complex tumor biological processes. Therefore, to perform outcome estimation in the --omics setting, it is more common to construct multifactor panels. Our results showed that the developed radiomic signature achieved satisfactory risk evaluation results for ER in the primary and external cohorts.

We then constructed a radiomic nomogram that incorporated clinical factors (the CA19‐9 level and clinical stage) and the radiomic signature, which showed favorable performance and improved risk evaluation accuracy in both the internal and external independent cohorts.

CA‐199 was identified as an independent prognostic predictor in this study, which was consistent with previous studies.[35](#jmri27024-bib-0035){ref-type="ref"}, [36](#jmri27024-bib-0036){ref-type="ref"}, [37](#jmri27024-bib-0037){ref-type="ref"} The level of CA19‐9 correlates closely with disease burden in patients, and a higher CA19‐9 value indicates an increased risk of tumor metastasis. However, CA19‐9 as a marker has limitations. For example, CA19‐9 is often elevated in patients with jaundice, which could result in overestimation of the disease burden.[26](#jmri27024-bib-0026){ref-type="ref"} Moreover, CA19‐9 levels correlate poorly with tumor differentiation, which is highly associated with prognosis in PC.[38](#jmri27024-bib-0038){ref-type="ref"} In our study, CA19‐9 alone archived an AUC of 0.672 for discrimination of ER in the training cohort. Therefore, CA19‐9 alone is not enough for accurate risk assessment of ER.

The clinical stage system stratifies PDAC according to three major parameters on images: primary tumor, regional lymph nodes, and distant metastases.[5](#jmri27024-bib-0005){ref-type="ref"} This criterion is fundamental to establish a prognosis in different malignancies. In the present study, we observed that patients in the later stage are more likely to have ER after surgery. However, the clinical stage system mainly focuses on anatomical radiological features, which might oversimplify the complexity of a tumor\'s biological behavior. Therefore, clinical stage alone is not enough for accurate risk evaluation of ER.

According to previous studies of PC, severe pain and obvious weight loss were also associated with poor prognosis.[39](#jmri27024-bib-0039){ref-type="ref"}, [40](#jmri27024-bib-0040){ref-type="ref"} However, our data failed to confirm these results. Pain can be related to infiltration of a tumor into surrounding nerves, vessels, or viscera. Different types of invasion can have varying impacts on prognosis. However, parameters such as pain might be subjective because of varying levels of sensitivity among patients to abdominal pain caused by the tumor. Weight loss indicates the malnutrition status of patients. In the present study, we observed a lower rate of weight loss compared with that in previous reports.[40](#jmri27024-bib-0040){ref-type="ref"} This could be related to the diverse ethnic population included. The tumors were identified by physical examination in many patients included in our study and were at an early stage without symptoms, which could also account for these results.

Finally, DCA showed that the radiomic nomogram outperformed the radiomic signature across a wide range of threshold probabilities, which revealed that the clinical parameters added incremental value to ER risk evaluation in both the primary and external cohorts.

The developed risk evaluation model has obvious advantages. Compared with gene expression tests based on invasive biopsies, the noninvasive characteristic of radiomic analysis lends itself to a wide range of applications for patients. In addition, biopsies have obvious limitations caused by sampling bias that could result from intratumoral heterogeneity, while radiomics represents a comprehensive assessment of the whole tumor. Moreover, the preoperative data used in the developed risk evaluation model are easily accessible, with little additional cost and show favorable results. These advantages and results are encouraging and promising.

*Limitations* {#jmri27024-sec-0027}
-------------

Our study has several limitations. First, selection bias might exist because of the retrospective design of our study. Second, this was a relatively small sample size. However, our cohort is still one of the largest with respect to radiomics and resectable PC. Third, we abandoned the diffusion‐weighted MR image with different b values over a long time period because of poor consistency between the two hospitals. The T~1~‐w, T~2~‐w, portal venous phase, and arterial phase were chosen to ensure that the cohorts were large enough to develop a stable model to evaluate ER risks.

*Conclusion* {#jmri27024-sec-0028}
------------

We developed a novel model incorporating a radiomic signature and clinical parameters to evaluate the ER risks of patients with resectable PC preoperatively. The accurate identification of this subgroup of early‐stage patients who would receive little benefit from upfront surgery might potentially help decision‐making for treatment strategies and clinical trials. Although the results are encouraging and promising, further validation of this evaluation model in a large and diverse population is still required.
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